Description
(AWP Alliance News) - Basilea Pharmaceutica AG reported that partner Asahi Kasei Therapeutics has started a Phase 2 pediatric study in Japan for antifungal Cresemba (isavuconazole) in children at risk of deep-seated fungal infections. No trial results have been presented yet, with the study set to generate future safety and pharmacokinetic data.
The move supports a potential expansion of Cresemba into Japan's pediatric market, where the drug is currently cleared only for adult use. Basilea also highlighted Cresemba's commercial momentum, citing global in-market sales of USD 782 million for April 2025 to March 2026, up 27% year over year.
https://www.globenewswire.com/NewsRoom/ReleaseNg/402501600
Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire on September 14, 2026, and is solely responsible for the information contained therein.
